Back to News
Oct 22, 2025 4:00 PM

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy

Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.

AATD causes emphysema when the body doesn’t produce enough of the protective alpha-1 antitrypsin (AAT) protein, leading to a breakdown of the lung’s air sacs (alveoli).

This genetic condition leads to the accumulation of enzymes, such as neutrophil elastase, which damage the lungs, resulting in symptoms like shortness of breath and a chronic cough.

The data ...